| 3.24 -0.17 (-4.99%) | 09-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.97  |
1-year : | 4.32 |
| Resists | First : | 3.4 |
Second : | 3.7 |
| Pivot price | 3.37 |
|||
| Supports | First : | 2.92 |
Second : | 2.42 |
| MAs | MA(5) : | 3.24 |
MA(20) : | 3.36  |
| MA(100) : | 3.29 |
MA(250) : | 3.93 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 30.5 |
D(3) : | 22.3 |
| RSI | RSI(14): 47.4 |
|||
| 52-week | High : | 7.17 | Low : | 2.76 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RXRX ] has closed above bottom band by 23.3%. Bollinger Bands are 33% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.37 - 3.39 | 3.39 - 3.41 |
| Low: | 3.18 - 3.2 | 3.2 - 3.22 |
| Close: | 3.21 - 3.24 | 3.24 - 3.27 |
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
Tue, 15 Sep 2026
RXRX: AI-driven drug discovery platform delivers first-in-class assets and major partnership milestones - TradingView
Tue, 15 Sep 2026
RXRX: AI-driven drug discovery engine delivers first-in-class assets and strong partnership milestones - TradingView
Fri, 11 Sep 2026
Recursion Pharmaceuticals (RXRX) CEO and President Najat Khan Se - GuruFocus
Thu, 10 Sep 2026
Recursion (NASDAQ: RXRX) CEO sells 22K shares under preset plan - Stock Titan
Thu, 10 Sep 2026
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today - Yahoo Finance
Tue, 18 Aug 2026
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 535 (M) |
| Held by Insiders | 5.1845e+008 (%) |
| Held by Institutions | 2.2 (%) |
| Shares Short | 180,760 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.716e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 759.6 % |
| Return on Equity (ttm) | -27.4 % |
| Qtrly Rev. Growth | 5.486e+007 % |
| Gross Profit (p.s.) | -56.17 |
| Sales Per Share | -52.88 |
| EBITDA (p.s.) | -3.66916e+008 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -350 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.07 |
| Price to Cash Flow | 2.02 |
| Dividend | 0 |
| Forward Dividend | 1.7792e+008 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|